Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Common arthritis drug also lowers blood pressure

Scientists have known for a while that methotrexate helps with inflammation, but it may also help...

AI enables precise gene editing

A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...

Shingles vaccine may reduce risk of heart attack and stroke 

Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...

Content from other channels on our network

Tas doctors "strongly oppose" any taxpayer-funded home birth scheme

Perich Centre for Robotics & Health Technology opens in Liverpool

Australia will soon have its own 'centre for disease control'. Let's not repeat the chaos of the US

Report: Sepsis more prevalent, deadly and costly than previously understood

Patient-centric digital pathway seeks to transform short-stay surgery

New food safety regulator for Victoria

Discovery improves flavour of Chinese spirits

Hyperspectral imaging for food grading

Walkers Chocolates introduces recyclable paper wrapper

Australians back egg industry amid biosecurity concerns

FieldComm Group announces unified device integration roadmap

WA announces legislation to drive industry investment

Livium and UoM partner on microwave technology for REE extraction

Australia moves towards Horizon Europe membership

Mitsubishi Electric to acquire Nozomi Networks